Bei Wang

5PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 24, 2026
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis.

|Nov 06, 2024
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection.

Christopher D Petro, Andrea T Hooper, Avery Peace

|Jun 26, 2020
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.

Janelle C Waite, Bei Wang, Lauric Haber

|Jan 10, 2020
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.

Dimitris Skokos, Janelle C Waite, Lauric Haber

|Nov 04, 2018
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8.

Bei Wang, Wen Zhang, Vladimir Jankovic

Pageof 1

Frequent Collaborators

4 joint publications

Jacquelynn Golubov

4 joint publications

Andrew J Murphy

3 joint publications

Matthew Sleeman

3 joint publications

Patrick Poon